Medpacto, ASCO adopted Vactosertib as the topic of clinical presentation

Medpacto, ASCO adopted Vactosertib as the topic of clinical presentation

Medpacto, American Society of Clinical Oncology (ASCO) adopted Vactosertib as the topic of clinical presentation Vactosertib-Keytruda combination therapy clinical trial data for colorectal cancer patients disclosed [April 6, 2021] Medpacto (CEO, Seong-Jin Kim) announced on the 6th that the clinical data for combination therapy with Vactosertib submitted to the American Society of Clinical Oncology (ASCO) have been adopted as the topic of official presentation. ASCO is a prestigious global society in the field of oncology, and more than 40,000 people including cancer specialists and global phar..........

원문링크 : Medpacto, ASCO adopted Vactosertib as the topic of clinical presentation

 등록된 다른 글

[2019.11.11] 메드팩토, 바이오유럽 참가해 해외 파트너링 추진

메드팩토, 백토서팁 골육종서 FDA ‘희귀의약품’ 지정

[21.04.14] 메드팩토, ASCO 연례회의서 다발골수종 병용임상 추가 채택

[2020.08.10] 메드팩토 미국 자회사 셀로람, 750만 달러 투자 유치

메드팩토, 1000억 원 투자유치 완료 '희귀난치성질환 허가용 임상 속도↑'

[2019.07.18] 메드팩토, 기술성평가 통과... 연내 코스닥 입성 목표

Medpacto Signs IIT Contract for Combination Therapy for Melanoma Patients

Medpacto Reveals Four Studies in AACR, U.S.